Regulatory & Policy

Systematic, data-driven science coverage · Sunday, September 13, 2026
More from Regulatory & Policy
Spinal MRI findings trigger FDA hold, derail RegenxBio’s RGX-121 filing
Regulatory & Policy

Spinal MRI findings trigger FDA hold, derail RegenxBio’s RGX-121 filing

The FDA's clinical hold on Navsunli (clemidsogene lanparvovec-sngl [RGX-121]), an investigational adeno-associated virus (AAV) gene therapy for...

Aug 24
ADARx's onvuzosiran secures FDA Fast Track for twice-yearly HAE prophylaxis approach
Regulatory & Policy

ADARx's onvuzosiran secures FDA Fast Track for twice-yearly HAE prophylaxis approach

San Diego-based ADARx Pharmaceuticals, Inc. received US FDA Fast Track Designation for onvuzosiran (ADX-324), a prekallikrein (PKK)-targeting small...

Aug 24
FDA fast tracks Erasca’s pan-RAS molecular glue after early pancreatic cancer responses
Regulatory & Policy

FDA fast tracks Erasca’s pan-RAS molecular glue after early pancreatic cancer responses

San Diego-based Erasca, Inc. (Nasdaq: ERAS) announced that the US FDA has granted Fast Track Designation (FTD) to ERAS-0015, an oral pan-RAS molecular glue,...

Aug 24
FDA accepts United Therapeutics' ralinepag NDA for PAH
Regulatory & Policy

FDA accepts United Therapeutics' ralinepag NDA for PAH

The US FDA has accepted for review a New Drug Application from United Therapeutics Corporation (Nasdaq: UTHR) for ralinepag, an investigational prostacyclin...

Aug 24
FDA extends deramiocel review three months as Capricor narrows indication to upper limb function
Regulatory & Policy

FDA extends deramiocel review three months as Capricor narrows indication to upper limb function

The US FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for deramiocel (CAP-1002), San Diego-based Capricor Therapeutics'...

Aug 24
HHS seeks input on new tiers for federal vaccine recommendations
Regulatory & Policy

HHS seeks input on new tiers for federal vaccine recommendations

Category: Regulatory Policy | Regulatory Body: HHS | Geography: United States | Policy Instrument: Request for Information

Aug 24
Orum moving CD123-targeted DAC into first-in-human testing against AML
Regulatory & Policy

Orum moving CD123-targeted DAC into first-in-human testing against AML

FDA clearance of an investigational new drug application for ORM-1153, a degrader-antibody conjugate (DAC) designed to deliver targeted protein degradation...

Aug 24
Scholar Rock withdraws EU apitegromab filing over manufacturing site issue
Regulatory & Policy

Scholar Rock withdraws EU apitegromab filing over manufacturing site issue

Cambridge, Massachusetts-based Scholar Rock (Nasdaq: SRRK) announced a series of regulatory updates on August 24, 2026, confirming that its Biologics...

Aug 24
The AllSci BriefFree, systematic R&D and deal news. Daily.
FDA sets cross-center framework for digital measures in clinical trials
Regulatory & Policy

FDA sets cross-center framework for digital measures in clinical trials

Category: Clinical Trial Reform | Regulatory Body: FDA (CBER, CDER, CDRH, OCE) | Geography: United States | Instrument: Guidance document

Aug 21
CStone to put EGFR/HER3 bispecific ADC to first-in-human test in China
Regulatory & Policy

CStone to put EGFR/HER3 bispecific ADC to first-in-human test in China

China's National Medical Products Administration (NMPA) has cleared CStone Pharmaceuticals (HKEX: 2616) to begin clinical trials of CS5007, an EGFR/HER3...

Aug 21
China's CDE launches PIONEER Program for cell and gene therapy products
Regulatory & Policy

China's CDE launches PIONEER Program for cell and gene therapy products

Category: Regulatory Policy | Regulatory Body: CDE (Center for Drug Evaluation, NMPA) | Geography: China | Instrument: Initiative launch

Aug 20
FDA grants Fast Track Designation to Rein's LTI-03 for idiopathic pulmonary fibrosis
Regulatory & Policy

FDA grants Fast Track Designation to Rein's LTI-03 for idiopathic pulmonary fibrosis

Austin, Texas-based Rein Therapeutics (Nasdaq: RNTX) announced that the US FDA has granted Fast Track Designation to LTI-03, a first-in-class inhaled...

Aug 20
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma
Regulatory & Policy

FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma

New York-based Nuvation Bio Inc. (NYSE: NUVB) announced that the US FDA has granted Fast Track Designation to safusidenib, an oral, brain-penetrant,...

Aug 20
Hengrui's licancopan wins China PNH approval after outperforming eculizumab in Phase III
Regulatory & Policy

Hengrui's licancopan wins China PNH approval after outperforming eculizumab in Phase III

China's National Medical Products Administration (NMPA) has approved Licancopan fumarate (HRS-5965) capsules, developed by Chengdu Suncadia Medicine Co.,...

Aug 20
FDA sets out potency testing approach for personalized cancer vaccines
Regulatory & Policy

FDA sets out potency testing approach for personalized cancer vaccines

Category: Regulatory Policy | Regulatory Body: FDA/CBER | Geography: United States | Policy Instrument: Guidance document | Topics: Potency assay...

Aug 20